Publication Brief
Our understanding of neuroinflammation and its role in central nervous system (CNS) diseases has significantly advanced. Neuroinflammation is pivotal in both the acute response and long-term recovery from acquired brain injuries like traumatic brain injury (TBI) and stroke, and in the pathology of diseases such as multiple sclerosis (MS). It’s also increasingly recognized as a key factor in neurodegenerative diseases like Alzheimer’s (AD) and Parkinson’s (PD), as well as neuropsychiatric conditions such as depression.
Cytokines, critical proteins involved in cell signaling during inflammation, are emerging as important biomarkers in understanding, diagnosing, and tracking the progression of neurological disorders. Research has consistently demonstrated altered cytokine levels in these diseases, highlighting their diagnostic potential.
This brief showcases a sampling of studies utilizing Simoa® digital immunoassay technology for ultra-sensitive cytokine measurement in neurology research. These studies often combine cytokine analysis with other key biomarkers like neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), Tau, phosphorylated Tau, and amyloid beta (Aβ).